Clinical Guides
Acromegaly
A clinically focused guide to adult acromegaly diagnosis and longitudinal care in India, integrating IGF-1 and GH interpretation, pituitary tumour control, comorbidity screening, surgery, medicines, radiotherapy and pregnancy planning.
MedNext Academy | 12 min read
Acromegaly
A clinically focused guide to adult acromegaly diagnosis and longitudinal care in India, integrating IGF-1 and GH interpretation, pituitary tumour control, comorbidity screening, surgery, medicines, radiotherapy and pregnancy planning.
Summary
Acromegaly is a chronic disorder of excessive growth hormone secretion, usually from a pituitary somatotroph adenoma, producing sustained elevation of insulin-like growth factor 1 and progressive multisystem disease. Facial and acral change may be subtle over years; patients often first present with headache, sweating, snoring, joint symptoms, carpal-tunnel syndrome, hypertension, diabetes, menstrual disturbance, sexual dysfunction or an incidental sellar mass. Diagnosis is biochemical before it is radiological: measure age-adjusted IGF-1 with a reliable assay, repeat or clarify discordant results, and use an oral glucose tolerance test for GH nonsuppression when clinically appropriate. Random GH alone is an unreliable diagnostic shortcut because secretion is pulsatile and assay characteristics vary. Once biochemical disease is established, pituitary MRI defines tumour anatomy and visual assessment is added when the optic apparatus is threatened. Transsphenoidal surgery is generally preferred for resectable disease and decompression, while somatostatin receptor ligands, pegvisomant and cabergoline are selected according to residual activity, tumour behaviour, comorbidity, availability and cost. Radiotherapy is a delayed-control option for selected persistent disease and requires lifelong pituitary surveillance. Care is not complete when IGF-1 normalizes: cardiovascular, respiratory, metabolic, musculoskeletal, endocrine and neoplastic risks need structured assessment. Pregnancy should be planned with specialist review because tumour size, disease activity, medicines and imaging influence surveillance. Indian pathways must account for uneven access to standardized IGF-1 assays, expert pituitary surgery and high-cost long-term therapy. This educational draft has been reviewed by the MedNext Clinical Team and is not a patient-specific protocol.
How Common Is It?
Acromegaly is uncommon, but the clinically important burden is greater than a simple prevalence figure suggests because recognition is often delayed and complications accumulate before diagnosis. Population studies use different case definitions, databases and ascertainment methods, producing heterogeneous estimates. Referral-centre cohorts overrepresent macroadenomas and complex treatment, whereas community data may miss people with modest biochemical activity or gradual phenotypic change. India does not have a complete national acromegaly registry from which a precise population prevalence or diagnostic delay can be claimed. Case volume also varies with access to endocrine testing and pituitary MRI. Most adult cases are sporadic pituitary adenomas; familial syndromes and ectopic growth-hormone-releasing hormone secretion are much rarer. Increased recognition through diabetes, sleep, dental, orthopaedic and neurosurgical services could identify cases earlier, but indiscriminate IGF-1 screening of low-risk populations is not evidence-based. The useful epidemiological lesson is therefore diagnostic vigilance: multiple characteristic features, progressive ring or shoe-size change, unexplained cardiometabolic disease or a pituitary mass should trigger case finding even when each individual complaint is common.
Risk Factors
Most patients have no modifiable antecedent risk factor because the underlying somatotroph adenoma arises sporadically. A family history of pituitary tumours, young age, gigantism, multiple endocrine neoplasia type 1, familial isolated pituitary adenoma or an AIP-associated family should prompt genetic and syndromic consideration. McCune-Albright syndrome and Carney complex are uncommon but relevant in distinctive phenotypes. Large tumours increase the chance of visual compromise, hypopituitarism and incomplete surgical resection; cavernous-sinus invasion predicts more difficult tumour control. Longer untreated disease permits hypertension, cardiomyopathy, obstructive sleep apnoea, glucose intolerance, arthropathy and vertebral fracture to evolve, so diagnostic delay is itself a risk amplifier. Pregnancy is not a cause, but physiological changes and withdrawal of medical therapy may influence tumour or biochemical surveillance. Diabetes, oestrogen exposure, renal or hepatic dysfunction, malnutrition and oral oestrogen can complicate interpretation of GH or IGF-1 rather than cause acromegaly. Rare ectopic GHRH secretion should be considered when pituitary findings are absent or hyperplasia rather than a discrete adenoma is present. Risk stratification after diagnosis therefore includes tumour anatomy, biochemical activity, age, cardiovascular status, sleep apnoea, glucose metabolism, colon history, thyroid nodularity, skeletal disease, other pituitary deficits and feasibility of definitive treatment.
Diagnosis
History
Ask about progressive enlargement of hands or feet, ring and shoe-size change, facial coarsening, jaw or dental spacing, sweating, skin tags, headache, visual symptoms, snoring, witnessed apnoea, daytime somnolence, arthralgia, back pain, paraesthesia, weakness, hypertension, diabetes, menstrual disturbance, galactorrhoea, reduced libido and erectile dysfunction. Compare dated photographs when appropriate. Document family pituitary disease, age at onset, pregnancy plans and medicines, especially oral oestrogen and glucose-altering treatment.
Examination
Assess blood pressure, BMI and waist, visual fields by confrontation, cranial nerves, facial and acral features, macroglossia, prognathism, interdental spacing, skin thickening, sweating, goitre, cardiac signs, peripheral nerve compression and joint limitation. Examine for features of hypopituitarism or MEN1. Phenotype supports suspicion but neither proves nor excludes biochemical disease.
Investigations
Measure serum IGF-1 using an age-adjusted, assay-specific reference range. Repeat an unexpected elevation, preferably with the same validated method while addressing pregnancy, puberty, malnutrition, liver or renal disease, poorly controlled diabetes and oestrogen effects. Contemporary consensus considers IGF-1 above 1.3 times the upper limit of normal diagnostic when typical acromegaly features are present. For equivocal or discordant findings, repeat IGF-1 with the same validated assay and consider GH suppression during a 75-g oral glucose tolerance test when clinically suitable. Interpret the nadir with assay-sensitive thresholds; a random GH is not a stand-alone diagnostic test. Discordant GH and IGF-1 results require specialist reassessment rather than averaging them. After biochemical confirmation, obtain contrast pituitary MRI, prolactin and other pituitary axes; perform formal perimetry for chiasmal proximity. Baseline assessment includes HbA1c or glucose, blood pressure, sleep-apnoea evaluation, ECG or echocardiography when indicated, thyroid examination, colon assessment according to age and risk, and vertebral-fracture consideration. Testing after treatment must respect timing, medicine pharmacology and assay consistency.
Differential Diagnosis
Familial coarse features, large hands, obesity, hypothyroidism, insulin resistance, pachydermoperiostosis and some genetic overgrowth syndromes can resemble acromegaly without GH excess. Pregnancy and puberty physiologically raise IGF-1 in context-specific ways, while malnutrition, hepatic failure, renal dysfunction and poorly controlled diabetes can distort the GH-IGF-1 relationship. Oral oestrogen may reduce hepatic IGF-1 and raise GH, producing biochemical discordance. A pituitary incidentaloma plus nonspecific symptoms is not diagnostic; the lesion may be nonfunctioning or secrete another hormone. Pseudoacromegaly describes an acromegaloid appearance without elevated IGF-1 or autonomous GH secretion and demands assessment of alternative metabolic or genetic causes. If IGF-1 is repeatedly raised but MRI does not show an adenoma, reconsider assay interference, physiological confounders, very small pituitary disease and rare ectopic GHRH secretion. Conversely, a normal age-adjusted IGF-1 obtained in a reliable assay generally argues strongly against active acromegaly, but repeating it is reasonable when clinical suspicion is compelling and a confounder is present. Diagnostic discipline prevents both missed disease and harmful labelling: phenotype triggers testing, validated biochemistry establishes activity, and imaging locates the source.
Management
Treatment seeks biochemical control, relief of mass effect, preservation of pituitary function, reduction of comorbidity and restoration of life expectancy and quality of life. Experienced transsphenoidal surgery is usually first-line for a resectable pituitary adenoma, especially when complete excision appears feasible or the optic apparatus is threatened. Outcome depends strongly on tumour size, invasion and surgeon expertise; postoperative GH and IGF-1 must be assessed at appropriate intervals rather than declaring cure immediately. Persistent or unresectable disease is managed with shared selection among long-acting first-generation somatostatin receptor ligands, pegvisomant, cabergoline, selected second-generation ligand therapy, further surgery or radiotherapy. Choice depends on degree of biochemical activity, residual tumour, receptor response, glucose status, gallbladder and liver risk, injection burden, access and cost. Combination therapy can improve control but increases complexity and expense. Stereotactic or fractionated radiotherapy may control residual tumour and hormones slowly; it is not an instant biochemical solution and creates a long-term risk of hypopituitarism. Alongside tumour-directed therapy, treat hypertension, diabetes, sleep apnoea, arthropathy, cardiovascular disease and pituitary deficits. Repeat MRI according to residual tumour and treatment, and use the same IGF-1 assay where possible. Evidence is strongest for biochemical and tumour endpoints; proof that every intervention reverses every established complication is limited. Persistent symptoms despite normalized markers deserve evaluation rather than automatic escalation of acromegaly therapy.
Prescribing Information
Long-acting octreotide or lanreotide suppresses GH secretion in a proportion of patients and may reduce tumour volume. Monitor clinical response, IGF-1, glucose, gastrointestinal effects, gallbladder disease, heart rate and thyroid or pituitary axes as relevant. Pasireotide can provide additional biochemical control in selected resistant disease but has a substantial hyperglycaemia burden; diabetes status and access to monitoring influence suitability. Pegvisomant blocks the GH receptor, so IGF-1 rather than serum GH guides dose adjustment; GH may rise and is not a marker of response. Monitor liver tests and periodic tumour imaging, particularly when residual adenoma exists. Cabergoline is an oral option most useful in modest biochemical activity or mixed GH-prolactin secretion, but response is less predictable than promotional simplicity suggests; higher cumulative exposure warrants valve-risk consideration according to dose and local practice. Drug availability and price vary in India, and biosimilar or formulation substitutions require careful verification rather than assumed equivalence. After surgery, adrenal, thyroid, gonadal and water-balance disturbances must be assessed. Radiotherapy does not remove the need for bridging medical treatment when activity persists and mandates lifelong surveillance for new pituitary deficiencies. Pregnancy usually prompts preconception review and often withdrawal of acromegaly medicines once pregnancy is confirmed, but treatment may be reconsidered for symptomatic tumour growth under specialist guidance. No medicine should be selected solely by one laboratory number without tumour, comorbidity and patient-preference context.
When to Refer
Refer every biochemically suspected case to endocrinology for confirmation, confounder review and coordinated pituitary evaluation. Early referral is preferable to ordering serial random GH measurements. A confirmed case should reach a pituitary multidisciplinary team with experienced neurosurgery, neuroradiology and endocrine pathology because first-operation quality materially affects remission. Urgent referral is needed for visual-field loss, ophthalmoplegia, sudden severe headache, altered consciousness or other features of apoplexy. Formal ophthalmology or neuro-ophthalmology assessment is indicated when MRI shows chiasmal contact or symptoms. Cardiology, sleep medicine, diabetes care, gastroenterology, rheumatology, pain services or spine expertise may be required according to comorbidity rather than as a routine checklist detached from clinical findings. Refer younger patients or those with familial disease for genetic assessment when syndromic criteria are met. Pregnancy planning needs endocrinology and obstetric review before conception, including tumour size, prior control, medicine strategy and symptom surveillance. If local access to IGF-1, pituitary MRI or medical therapy is limited, referral documentation should include phenotype, dates of photographs or size changes, assay and reference interval, GH testing method, visual findings and comorbidities. Long-distance patients need a shared plan defining which measurements can be performed locally and which decisions require the tertiary centre.
Red Flags
Sudden severe headache, vomiting, visual-field loss, diplopia, ptosis, ophthalmoplegia, meningism or reduced consciousness may signal pituitary apoplexy and requires emergency glucocorticoid assessment or cover, imaging and neurosurgical-endocrine involvement. Progressive visual loss or new cranial-nerve dysfunction suggests tumour expansion even without apoplexy. Chest pain, syncope, acute breathlessness or neurological deficit must be evaluated as cardiovascular emergencies; acromegaly does not make ordinary emergency pathways optional. Severe daytime somnolence, witnessed prolonged apnoeas or perioperative airway concern requires prompt sleep and anaesthetic assessment because macroglossia and soft-tissue enlargement can create difficult airways. Marked hyperglycaemia or ketosis may be worsened by active disease or pasireotide. After surgery, hypotension, polyuria, polydipsia, severe hyponatraemia, confusion or inability to retain oral steroids can indicate pituitary emergencies. During pregnancy, new headache or visual symptoms demand urgent specialist assessment rather than reliance on biochemical markers that are difficult to interpret physiologically. A rapidly enlarging lesion or discordant aggressive behaviour should trigger pathology review and specialist escalation. Red flags are acted on clinically while biochemical confirmation or routine surveillance continues; waiting for the next scheduled IGF-1 can cause preventable harm.
Indian Clinical Context
Diagnostic and treatment capacity varies from high-volume pituitary units to settings without an age-adjusted IGF-1 assay. Reports should identify the platform, reference interval and patient age; values from different assays should not be trended as if identical. Oral glucose GH testing requires correct glucose preparation, timed sampling and an assay capable of measuring low GH concentrations. MRI protocols and radiology experience influence detection of small or invasive tumours. When feasible, referral to an experienced transsphenoidal surgeon is a value intervention because an incomplete first operation may commit the patient to years of costly medicines. Long-acting somatostatin analogues and pegvisomant can be financially inaccessible or inconsistently supplied; care plans should state realistic alternatives, monitoring and the danger of interrupted therapy without pretending that cost-constrained choices have identical evidence. Radiotherapy may be more available than lifelong high-cost therapy, but delayed biochemical effect and hypopituitarism must be explained. Diabetes, hypertension and sleep-apnoea care can often be shared with local clinicians, reducing travel while retaining centralized pituitary decisions. Colonoscopy, echocardiography and sleep studies should be risk- and symptom-informed when capacity is constrained, not abandoned or performed mechanically. Patient education in a preferred language, copies of laboratory methods and imaging, and a written follow-up calendar improve continuity across public and private systems. Indian data gaps should be labelled as gaps rather than filled with imported prevalence or outcome claims.
NMC Competency Mapping
Acromegaly integrates endocrine physiology with clinical medicine, surgery, radiology, pharmacology, pathology and communication. A learner should recognize a pattern from serial appearance and multisystem symptoms, construct a focused history and examination, select age-adjusted IGF-1 as the initial biochemical test, explain glucose-suppressed GH testing, and avoid using random GH as a stand-alone diagnosis. Imaging competence includes knowing that MRI follows biochemical confirmation and identifying when formal visual fields are required. Management competencies include comparing transsphenoidal surgery, receptor-directed or secretion-directed medicines and delayed-effect radiotherapy, while acknowledging evidence and access limitations. The learner should screen rationally for hypertension, dysglycaemia, sleep apnoea, cardiomyopathy, thyroid disease, skeletal complications and pituitary deficits. Safety assessment should include apoplexy, airway risk and postoperative adrenal or water-balance emergencies. Communication should cover chronic surveillance, fertility and pregnancy, uncertain reversibility of complications, costs and shared decisions. Exact institutional competency codes should be assigned from the current 2024 NMC curriculum and local logbook rather than invented. Suitable assessment combines phenotype recognition, IGF-1 and GH interpretation, MRI reasoning, a treatment comparison and a longitudinal follow-up plan.
Key Exam Pearls for NEET PG
Screen a patient with a convincing phenotype using age-adjusted IGF-1, not a random GH. Confirm an elevated or equivocal result and address assay and physiological confounders. Failure of GH suppression during a 75-g oral glucose test supports the diagnosis in the appropriate context, but the nadir threshold depends on assay sensitivity and current consensus. MRI localizes a lesion after biochemical evidence; an incidental pituitary mass alone does not establish acromegaly. The usual source is a somatotroph adenoma, while ectopic GHRH is rare. Transsphenoidal surgery is preferred for many resectable tumours, and cavernous-sinus invasion lowers the chance of surgical remission. Somatostatin receptor ligands suppress secretion; pegvisomant blocks peripheral GH action, so monitor IGF-1 rather than GH; cabergoline is most useful in selected modest or mixed secretion. Pasireotide can worsen hyperglycaemia. Radiotherapy acts slowly and can cause delayed hypopituitarism. Normalizing IGF-1 does not erase established sleep, joint, cardiovascular or skeletal disease, so comorbidity follow-up continues. Pregnancy management is planned, usually with medicine review and symptom-led tumour surveillance. Do not confuse pseudoacromegaly with biochemical disease. For examinations, state diagnostic confirmation, tumour localization, comorbidity assessment, definitive therapy and monitoring as separate steps rather than collapsing them into one slogan.
Frequently Asked Questions
Is a random growth hormone result enough to diagnose acromegaly?
No. GH secretion is pulsatile, and concentration varies with sleep, stress, exercise, nutrition, glucose and assay method. Age-adjusted IGF-1 is the usual initial biochemical test. Typical features with IGF-1 above 1.3 times the age-adjusted upper limit support diagnosis under contemporary consensus; equivocal results may need repeat IGF-1 and glucose-suppressed GH testing. The laboratory's assay and reference interval should accompany every interpretation because numerical thresholds are not universally transferable.
Why can acromegaly symptoms continue after IGF-1 becomes normal?
Structural joint disease, vertebral fracture, nerve compression, sleep apnoea and cardiac remodelling may not fully reverse when biochemical control is achieved. Some symptoms have another cause, while assay variation can complicate interpretation. Continued symptoms therefore prompt targeted comorbidity assessment and confirmation of disease control rather than automatic escalation of pituitary treatment. Rehabilitation, analgesia, sleep therapy or ordinary cardiometabolic care may be more helpful than changing tumour-directed medicine.
Which treatment is preferred first for a pituitary adenoma causing acromegaly?
Experienced transsphenoidal surgery is generally preferred for a resectable adenoma, especially when complete removal appears feasible or mass effect needs relief. Invasive anatomy, surgical risk and local expertise modify that choice. Persistent disease may need somatostatin receptor ligands, pegvisomant, cabergoline, further surgery or radiotherapy selected through multidisciplinary discussion. Remission is established with appropriately timed postoperative biochemistry, not the operating note or an early single GH value.
Can a woman with acromegaly safely plan pregnancy?
Many women can pursue pregnancy after preconception review. The team assesses tumour size, visual risk, biochemical control, fertility, pituitary deficits and which medicines should be stopped or continued. Biochemical markers are harder to interpret during pregnancy, so follow-up emphasizes symptoms and visual assessment, with MRI without gadolinium and treatment reserved for clinically significant tumour concerns. Endocrinology and obstetrics should agree in advance how severe headache, visual change or tumour growth will be investigated.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic